Loss of TET2 with reduced genomic 5-hmC is associated with adverse-risk AML. Pethusamy K, Seethy A, Dhar R, Karmakar A, et al. Leuk Lymphoma 2022;63:3426-3432.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Pethusamy K, Seethy A, Dhar R, Karmakar A, et al. Loss of TET2 with reduced genomic 5-hmC is associated with adverse-risk AML. Leuk Lymphoma 2022;63:3426-3432.
PMID: 36165590